Stephen K. Brannan - Dec 30, 2021 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Chief Medical Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol
KRTX
Transactions as of
Dec 30, 2021
Transactions value $
-$926,023
Form type
4
Date filed
1/3/2022, 06:06 PM
Previous filing
Dec 2, 2021
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $13.6K +2.5K +12.5% $5.45* 22.5K Jan 3, 2022 Direct
transaction KRTX Common Stock Options Exercise $71.1K +7.73K +34.35% $9.20* 30.2K Jan 3, 2022 Direct
transaction KRTX Common Stock Sale -$1.01M -7.73K -25.57% $130.79 22.5K Jan 3, 2022 Direct F1
transaction KRTX Common Stock Gift $0 -15K -66.67% $0.00 7.5K Dec 30, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -2.5K -5.41% $0.00 43.7K Jan 3, 2022 Common Stock 2.5K $5.45 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -7.73K -10.24% $0.00 67.7K Jan 3, 2022 Common Stock 7.73K $9.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2021.
F2 This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F3 This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of March 21, 2019.